Breaking News

Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022

Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022

CRANFORD, N.J., Could 18, 2022 /PRNewswire/ — Citius Prescription drugs, Inc. (“Citius” or the “Corporation”) (Nasdaq: CTXR), a late-phase biopharmaceutical enterprise establishing and commercializing to start with-in-course crucial care goods, these days introduced that it will current at the H.C. Wainwright Worldwide Investment decision Meeting staying held Might 23-26, 2022. Leonard Mazur, Chairman and CEO of Citius, will discuss the Firm’s modern business developments and impending milestones.

H.C. Wainwright Worldwide Trader Conference

Presentation day and time:

Tuesday, May perhaps 24, 2022 at 11:00 a.m. ET

Area:

Digital and at the Fontainebleau Miami Beach Hotel, Miami Beach front, Florida

Registration:

Visit the conference site for in-person or virtual registration

Live webcast:

Register listed here to check out

Webcast replay:

Available for 90 times

Fascinated events may well routine 1-on-1 meetings with Citius management by registering by way of the celebration system or contacting the Firm’s trader relations staff.

About Citius Pharmaceuticals, Inc.

Citius is a late-stage biopharmaceutical business committed to the enhancement and commercialization of 1st-in-course vital care goods, with a concentration on oncology, anti-infectives in adjunct most cancers care, exclusive prescription solutions, and stem mobile therapies. The Enterprise has two late-phase product candidates, Mino-Lok®, an antibiotic lock resolution for the therapy of patients with catheter-associated bloodstream bacterial infections (CRBSIs), which is now enrolling people in a Period 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an original sign in cutaneous T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Section 3 trial. Mino-Lok® was granted Rapid Track designation by the U.S. Food stuff and Drug Administration (Fda). I/ONTAK has acquired orphan drug designation by the Food and drug administration for the procedure of CTCL and peripheral T-cell lymphoma (PTCL). By way of its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell procedure derived from induced pluripotent stem cells (iPSCs) for acute respiratory situations, with a in the vicinity of-time period concentration on acute respiratory distress syndrome (ARDS) associated with COVID-19. For additional details, please go to www.citiuspharma.com.

Investor Relations for Citius Pharmaceuticals:
Ilanit Allen
Vice President, Trader Relations and Corporate Communications
T: 908-967-6677 x113
E: [email protected]

Citius Prescribed drugs, a late-phase biopharmaceutical corporation (PRNewsfoto/Citius Prescribed drugs, Inc.)

Cision

Cision

View initial material to obtain multimedia:https://www.prnewswire.com/information-releases/citius-prescribed drugs-to-existing-at-the-hc-wainwright-world-wide-expense-conference-on-may perhaps-24-2022-301549451.html

Source Citius Prescription drugs, Inc.